


# NOVEL DRUG DELIVERY SYSTEMS

PART 1



Editors:

**Atish S. Mundada**

**Alap Choudhari**

**Bentham Books**

# **Novel Drug Delivery Systems** *(Part 1)*

Edited by

**Atish S. Mundada**

*Department of Pharmaceutics  
SNJBs SSDJ College of Pharmacy  
Chandwad, Nashik, Maharashtra, India*

&

**Alap Chaudhari**

*Teva Pharmaceutical  
United States*

## **Novel Drug Delivery Systems (Part 1)**

Editors: Atish S. Mundada and Alap Choudhari

ISBN (Online): 978-981-5274-16-5

ISBN (Print): 978-981-5274-17-2

ISBN (Paperback): 978-981-5274-18-9

© 2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

<b>FOREWORD I</b> .....	i
<b>FOREWORD II</b> .....	ii
<b>PREFACE</b> .....	iii
<b>DEDICATION</b> .....	v
<b>LIST OF CONTRIBUTORS</b> .....	vi
<b>CHAPTER 1 CONTROLLED DRUG DELIVERY SYSTEMS: CONCEPTS AND RATIONALE</b> 1	
<i>Vipul D. Prajapati, Princy Shrivastav and Kavita Suthar</i>	
<b>INTRODUCTION</b> .....	2
Historical Overview .....	2
Rationale Behind CDDS .....	2
Classification of Controlled Release Drug Delivery Systems (CRDDS) .....	5
<i>Based on Route of Administration</i> .....	5
<i>Based on Release Mechanism</i> .....	7
<i>Based on Design</i> .....	8
<i>Based on Matrix Type</i> .....	9
<i>Based on Stimulus Responsive Systems</i> .....	10
<b>DESIGN AND FORMULATION OF CDDS</b> .....	12
Selection of Drug Candidates .....	13
<i>Physicochemical Properties</i> .....	13
<i>Therapeutic Response</i> .....	13
<i>Pharmacokinetics</i> .....	14
<i>Pharmacodynamics</i> .....	14
<i>Safety and Tolerability</i> .....	14
<i>Patient Population</i> .....	14
<i>Regulatory Considerations</i> .....	14
Polymer Selection and Drug-Polymer Compatibility .....	14
<i>Biocompatibility</i> .....	14
<i>Degradability</i> .....	14
<i>Drug Loading and Release</i> .....	15
<i>Mechanical Properties</i> .....	15
<i>Drug Stability</i> .....	15
<i>Drug Solubility</i> .....	15
<i>Manufacturability</i> .....	15
Manufacturing Techniques .....	15
Regulatory Considerations .....	19
<b>PRINCIPLE OF CONTROLLED DRUG RELEASE</b> .....	20
Mechanisms of Drug Release .....	20
<i>Diffusion-based Release</i> .....	20
<i>Erosion-based Release</i> .....	21
<i>Osmosis-based Release</i> .....	21
Mathematical Modelling of Drug Release .....	21
<b>THERAPEUTIC APPLICATIONS OF CONTROLLED DRUG DELIVERY</b> .....	22
Chronic Pain Management .....	22
Cancer Treatment .....	22
Diabetes Management .....	23
Other Therapeutic Areas .....	24
<b>FUTURE TRENDS AND EMERGING TECHNOLOGIES</b> .....	24
Nanotechnology in Drug Delivery .....	24

Personalized Medicine and Drug Delivery .....	26
Advancements in Drug Delivery Devices .....	27
Microneedles for Drug Delivery .....	28
<b>CHALLENGES WHILE DEVELOPING CDDS</b> .....	29
<b>CONCLUSION</b> .....	30
<b>REFERENCES</b> .....	31
<b>CHAPTER 2 PHARMACOKINETIC CONSIDERATIONS FOR CONTROLLED-RELEASE</b>	
<b>DOSAGE FORMS</b> .....	39
<i>Deepak S. Khobragade, Surendra S. Agrawal and Mrunali S. Potbhare</i>	
<b>INTRODUCTION</b> .....	40
<b>EXAMPLES OF CDDS</b> .....	41
Transdermal Patches .....	41
Microspheres and Nanoparticles .....	41
Implants .....	41
Osmotic Pumps .....	41
<b>ADVANTAGES OF CONTROLLED DRUG DELIVERY SYSTEMS</b> .....	42
Enhanced Therapeutic Efficacy .....	42
Minimized Systemic Side Effects .....	42
Increased Drug Bioavailability .....	42
Improved Patient Compliance .....	42
Reduced Drug Resistance .....	42
Personalized Medicine .....	42
Combination Therapy Optimization .....	43
Prolonged Drug Release .....	43
<b>ROUTES OF ADMINISTRATION FOR CDDS</b> .....	43
Oral Route .....	43
Transdermal Route .....	43
Intravenous (IV) Route .....	43
Intramuscular (IM) and Subcutaneous (SC) Routes .....	43
Implants and Depots .....	44
<b>DESIRED BIOPHARMACEUTICAL CHARACTERISTICS OF DRUG TO QUALIFY</b>	
<b>FOR CDDS</b> .....	47
Molecular Weight or Size .....	47
Solubility .....	47
Apparent partition coefficient (APC) .....	47
Low Toxicity and Side Effects .....	48
Therapeutic Index .....	48
Sufficient Half-Life .....	48
General absorption mechanism .....	48
Basic Pharmacokinetic Parameters .....	49
<i>Biological Half-life (<math>t_{1/2}</math>)</i> .....	49
<i>Minimum Effective Concentration (MEC)</i> .....	50
<i>Dose Size and Extent Of Duration</i> .....	50
<i>Total Clearance (CL)</i> .....	50
<i>The Terminal Disposition Rate Constant (<math>K_e</math> or <math>\lambda_z</math>)</i> .....	50
<i>Apparent Volume of Distribution (<math>V_z</math>)</i> .....	51
<i>Absolute Bioavailability (F)</i> .....	51
<i>Intrinsic Absorption Rate Constant (<math>K_a</math>)</i> .....	51
<i>Therapeutic concentration (<math>C_{ss}</math>)</i> .....	51
Drug Absorption .....	51

Factors Affecting Absorption .....	52
<i>Permeability Through Membranes</i> .....	52
<i>Solubility of Drug</i> .....	52
<i>Drug Ionization</i> .....	52
<i>Site Specific Conditions</i> .....	52
<i>Hepatic Metabolism</i> .....	52
<i>Interaction with Transporters</i> .....	52
<i>Interactions Between Food and Drug</i> .....	53
<i>Size of Particle in Formulation</i> .....	53
<i>Enzyme Activity</i> .....	53
<i>Rapid Onset of Action</i> .....	54
<i>Short Duration of Action</i> .....	54
<i>Fluctuating Drug Levels</i> .....	54
<i>Delay in Action Onset</i> .....	54
<i>Long Action Duration</i> .....	54
<i>Steady-state Drug Levels</i> .....	54
<i>Reduced Peak Concentrations</i> .....	54
Drug Distribution .....	55
<i>Tissue Penetration</i> .....	55
<i>Rapid Equilibration</i> .....	56
<i>Potential for Elevated Peak Concentrations</i> .....	56
<i>Short Duration of High Concentrations</i> .....	56
<i>Prolonged Exposure</i> .....	56
<i>Gradual Equilibration</i> .....	56
<i>Reduced Peak Concentrations</i> .....	56
<i>Selective Targeting</i> .....	56
<i>Drug Efficacy</i> .....	57
<i>Safety</i> .....	57
<i>Dosage Regimen</i> .....	57
<i>Combination Therapy</i> .....	57
<i>Disease Characteristics</i> .....	57
Drug Metabolism .....	57
<i>Phase I Reactions</i> .....	58
<i>Phase II Reactions</i> .....	58
<i>Bioavailability</i> .....	58
<i>Prodrugs</i> .....	58
<i>Drug Elimination</i> .....	59
<i>Half-Life</i> .....	59
<i>Drug-Drug Interactions</i> .....	59
<i>Toxicity and Adverse Effects</i> .....	59
<i>Cytochrome P450 (CYP) Enzymes</i> .....	59
<i>Uridine Diphosphate-glucuronosyltransferases, or UGTs</i> .....	60
<i>Sulfotransferases (SULTs)</i> .....	60
<i>Flavin-Containing Monooxygenases (FMOs)</i> .....	60
Drug Elimination .....	60
<i>Renal Excretion</i> .....	60
<i>Hepatic Clearance</i> .....	61
<i>Other Clearance Mechanisms</i> .....	61
<i>Dosing Frequency</i> .....	62
<i>Steady-State Concentrations</i> .....	62
<i>Withdrawal</i> .....	62



<i>Dose Adjustments</i> .....	62
<i>Minimizing Fluctuations</i> .....	62
<i>Duration of Action</i> .....	62
<b>INFLUENCE OF ENZYMES ON PHARMACOKINETICS OF CDDS</b> .....	62
Bioavailability Modification .....	62
Drug-Drug Interactions .....	63
Impact on Pharmacokinetics .....	63
Prodrug Activation .....	63
<b>BIOAVAILABILITY OF CONTROLLED DRUG DELIVERY SYSTEM</b> .....	63
Methods for Determining Bioavailability in CDDS .....	63
<i>Pharmacokinetic Studies</i> .....	63
<i>Relative Bioavailability Studies</i> .....	64
<i>Steady-State Analysis</i> .....	64
<i>Bioequivalence Studies</i> .....	64
<i>Imaging Techniques</i> .....	64
<b>CHALLENGES AND CONSIDERATIONS IN THE BIOAVAILABILITY ASSESSMENT OF CDDS</b> .....	64
Release Mechanism .....	64
Targeted Delivery .....	65
Variability .....	65
Sample Collection .....	65
Regulatory Considerations .....	65
<b>IMPACT OF DRUG-DRUG INTERACTIONS ON PHARMACOKINETICS OF CDDS</b> ....	65
Absorption Interactions .....	66
<i>pH-Dependent Drug Delivery Systems and Acid-Suppressing Medications</i> .....	66
<i>Interactions Affecting Gastric Emptying Time</i> .....	66
<i>Complexation or Chelation Interactions</i> .....	67
<i>Alterations in Intestinal Permeability</i> .....	67
Distribution Interactions .....	67
<i>Protein Binding Interactions</i> .....	67
<i>Drug-Drug Interactions Affecting Tissue Penetration</i> .....	67
<i>pH-dependent Tissue Accumulation</i> .....	68
<i>Efflux Transporter Interactions</i> .....	68
<i>Changes in Blood Flow</i> .....	68
Metabolism Interactions .....	68
<i>Cytochrome P450 (CYP) Enzyme Interactions</i> .....	68
<i>Prodrug Activation</i> .....	69
<i>Herb-Drug Interactions</i> .....	69
<i>Genetic Variations in Metabolizing Enzymes</i> .....	69
<i>Competition for Metabolic Pathways</i> .....	70
Elimination Interactions .....	70
<i>Renal Clearance Interactions</i> .....	70
<i>Hepatic Clearance Interactions</i> .....	71
<i>Gastrointestinal Interactions</i> .....	71
<i>Changes in pH and Drug Elimination</i> .....	71
<i>Drug-Drug Interactions Affecting Elimination</i> .....	72
<b>PHARMACOKINETICS OF NANO-BASED DRUG DELIVERY SYSTEMS</b> .....	72
Absorption .....	73
Distribution .....	73
Metabolism .....	74
Excretion .....	74

<b>PHARMACOKINETICS OF MICRONEEDLE</b> .....	74
<b>PHARMACOKINETIC MODELING OF CDDS</b> .....	75
Compartmental Models .....	75
Non-Compartmental Models .....	75
Physiologically Based Pharmacokinetic (PBPK) Models .....	76
Monte Carlo Simulation .....	76
<b>STEPS IN PHARMACOKINETIC MODELING FOR CDDS</b> .....	76
Formulation Characterization .....	76
Input Data Collection .....	76
Model Selection and Development .....	76
Parameter Estimation .....	76
Model Validation and Prediction .....	77
<b>STATISTICAL METHODS FOR DETERMINING PHARMACOKINETIC</b>	
<b>PARAMETERS</b> .....	77
Exploratory Data Analysis Methods .....	77
Multivariate Approach (MANOVA) .....	77
Model Dependent Methods .....	78
Linear or First-order Regression Model .....	78
Nonlinear Regression Models .....	79
Quadratic Model or Second-order Regression Model .....	79
<b>CONSTRAINTS ASSOCIATED WITH EXCLUSIVELY EMPLOYING</b>	
<b>PHARMACOKINETICS FOR THE DEVELOPMENT OF CONTROLLED-RELEASE</b>	
<b>DELIVERY SYSTEMS</b> .....	79
<b>CONCLUSION</b> .....	80
<b>REFERENCES</b> .....	81

**CHAPTER 3 POLYMERS: BACKBONE OF CONTROLLED DRUG DELIVERY** ..... 87

*Shweta H. Shahare, Hitesh V. Shahare, Nayana S. Baste and Atish S. Mundada*

<b>INTRODUCTION</b> .....	87
<b>TYPES OF POLYMERS</b> .....	88
Classifications Based on Source of Origin .....	89
<i>Natural Polymers</i> .....	89
<i>Semi-synthetic Polymers</i> .....	89
<i>Synthetic Fibres</i> .....	89
Classifications Based on the Structure .....	89
<i>Linear Polymers</i> .....	89
<i>Branching Polymers</i> .....	89
<i>Network or Cross-Linked Polymers</i> .....	89
Classifications Based on Polymerization Process .....	90
<i>Addition Polymers</i> .....	90
<i>Condensation Polymers</i> .....	90
Classifications Based on Molecular Forces .....	90
<i>Elastomer</i> .....	90
<i>Fibers</i> .....	90
<i>Thermoplastic Polymers</i> .....	91
<i>Thermosetting Polymers</i> .....	91
Classifications Based on the Homogeneity of Polymers .....	91
Classifications Based on Development Polymerization .....	91
<i>Chain Expansion Polymerization</i> .....	91
<i>Step Growth Polymerization</i> .....	91
Classification Based on Biostability .....	91

<i>Biodegradable</i> .....	91
<i>Non-biodegradable</i> .....	92
<b>PROPERTIES OF POLYMERS</b> .....	92
Chemical Properties .....	92
Thermal Properties .....	92
Mechanical Properties .....	93
Viscoelastic Properties .....	93
Drug Release Mechanism from Polymer .....	93
<i>Diffusion</i> .....	93
<i>Degradation</i> .....	93
<i>Swelling</i> .....	94
Advantages of Polymers .....	94
<b>CONTROLLED DRUG DELIVERY SYSTEM WITH POLYMERS</b> .....	94
Natural Polymers .....	95
<i>Protein-Based Polymers</i> .....	95
<i>Carbohydrate-Based Polymers</i> .....	98
Synthetic Polymers .....	102
<i>Polyhydroxy Butyrate</i> .....	103
<i>Poly(lactic Acid)</i> .....	103
<i>Poly(<math>\epsilon</math>-Caprolactone)</i> .....	104
<i>Polyglutamic Acid</i> .....	104
<i>Polyamide</i> .....	104
<i>Poly (2-Hydroxyethyl Methacrylate)</i> .....	105
<i>Poly (Vinyl Alcohol)</i> .....	105
<i>Poly (N-Vinyl Pyrrolidone)</i> .....	105
<i>Poly (methylmethacrylate)</i> .....	106
<i>Poly (Acrylic Acid)</i> .....	106
<i>Poly (Ethylene Glycol)</i> .....	107
<i>Polyanhydrides</i> .....	107
<i>Diblock Copolymer</i> .....	107
<i>Triblock Copolymer</i> .....	108
<b>RECENT ADVANCES IN POLYMERIC DRUG DELIVERY SYSTEMS</b> .....	108
Enteract Hpmcas Polymers .....	109
AFFINISOL Solubility Enhancing Polymers .....	109
Amberlite and Duolite Ion Exchange Resins .....	109
Ethocel .....	110
Polyox Water-soluble Resins .....	110
<b>POLYMERIC MICRONEEDLE-BASED DRUG DELIVERY SYSTEM</b> .....	111
Design Strategies of Long-acting Polymeric Microneedles .....	111
<b>FACTORS AFFECTING BIODEGRADATION OF POLYMERS</b> .....	111
Chemical Structure .....	112
Chemical Composition .....	112
Repeat Unit Distribution .....	112
Presence of Ionic Groups .....	112
Unexpected Units or Chain Defects .....	113
Configuration Structure .....	113
Molecular Weight .....	113
Molecular-Weight Distribution .....	113
Morphology .....	114
Low-Molecular-Weight Compounds .....	114
Processing Conditions .....	114

Annealing .....	114
Sterilization Process .....	114
Storage History .....	115
Shape of the Polymer .....	115
Site of Implantation .....	115
Adsorbed and Absorbed Compounds (Water, Lipids, Ions, etc.) .....	115
Physicochemical Factors (Ion Exchange, Ionic Strength, pH) .....	116
<b>POLYMERS FOR RESPONSE-BASED RELEASE</b> .....	116
Temperature-based Polymers .....	116
pH-sensitive Polymers .....	117
<i>pH-responsive Acidic Polymer</i> .....	117
<i>pH-responsive Basic Polymer</i> .....	117
<i>pH-responsive Natural Polymer</i> .....	117
Based on Redox Potential Polymers .....	117
Polymers that Respond to Glucose .....	117
Ionic Potency .....	118
Species of Chemical .....	118
Enzyme-Substrate .....	118
Magnetic Field Responsive Polymers .....	118
Ultrasound Irradiation .....	119
<b>CONCLUSION</b> .....	119
<b>REFERENCES</b> .....	119

#### **CHAPTER 4 MICROENCAPSULATION AS A TOOL FOR CONTROLLED DRUG DELIVERY** .....

<i>Rajendra T. Mogal and Moreshwar P. Patil</i> .....	128
<b>INTRODUCTION</b> .....	129
Reasons for Microencapsulation .....	129
<b>FORMULATION CONSIDERATION</b> .....	130
Core Material .....	130
Coating Materials .....	131
<i>Classification of Coating Material</i> .....	132
Types of Microcapsules .....	132
<b>MICROENCAPSULATION TECHNIQUES</b> .....	133
Mechanical Processes .....	133
Chemical Processes .....	133
Physico-chemical Processes .....	133
<i>Air Suspension</i> .....	133
<i>Pan Coating</i> .....	135
<i>Spray Drying and Spray Congealing</i> .....	135
<i>Multi-orifice-centrifugal Process</i> .....	136
<i>Solvent Evaporation/Solvent Extraction</i> .....	137
<i>Suspension Cross-linking</i> .....	138
<i>Extrusion through a Nozzle</i> .....	138
<i>Vibrational Jet/Electrostatic Extrusion</i> .....	138
<i>Freeze-drying</i> .....	139
<i>Supercritical Fluid (SCF) Process</i> .....	139
<i>Coacervation-phase Separation</i> .....	140
<b>DRUG RELEASE MECHANISM</b> .....	142
Diffusion .....	143
Swelling and Dissolution .....	144

Erosion and Degradation .....	145
Osmosis .....	145
<b>POLYMERS USED IN CONTROLLED-RELEASE MICROCAPSULES</b> .....	146
Natural Polymers .....	146
<i>Chitosan</i> .....	146
<i>Alginate</i> .....	147
<i>Gelatin</i> .....	148
<i>Cellulose</i> .....	149
<i>Pectin</i> .....	150
Synthetic Polymers .....	151
<i>Poly(L-lactic Acid) (PLA) and Poly(Lactic-coglycolic Acid) (PLGA)</i> .....	151
<i>Poly(<math>\epsilon</math>-caprolactone) (PCL)</i> .....	152
<i>Polyvinyl Alcohol (PVA)</i> .....	152
<i>Poly(methyl Methacrylate) (PMMA)</i> .....	153
<b>CHARACTERIZATION AND EVALUATION OF MICROCAPSULES</b> .....	154
Particle Size Analysis .....	154
Particle Morphology .....	154
Drug Loading Efficiency, Encapsulation Efficiency and % Yield .....	154
Fourier Transform Infra-Red (FTIR) Spectral Analysis .....	155
Differential Scanning Calorimetry (DSC) Analysis .....	155
Thermogravimetric Analysis (TGA) .....	155
X-ray Diffraction (XRD) .....	155
Raman Spectroscopy .....	155
Rheological Properties .....	155
<i>Angle of Repose</i> .....	156
<i>Compressibility Index</i> .....	156
<i>Hausner's Ratio</i> .....	156
Swelling Studies .....	156
In vitro Drug Release Studies .....	157
Drug Release Kinetic Analysis .....	157
<i>Zero Order</i> .....	157
<i>First Order</i> .....	158
<i>Higuchi</i> .....	158
<i>Hixon-Crowell Cube Root Law</i> .....	158
<i>Korsmeyer-Peppas Model</i> .....	158
<i>Kopcha Model</i> .....	159
In vivo drug release study .....	159
<b>CHALLENGES OF DRUG MICROENCAPSULATION</b> .....	159
<b>COMMERCIALY AVAILABLE MICROENCAPSULATED PHARMACEUTICAL PRODUCTS</b> .....	160
<b>CONCLUSION</b> .....	162
<b>REFERENCES</b> .....	162
<b>CHAPTER 5 COMPREHENSIVE INSIGHTS INTO MUCOADHESIVE DRUG DELIVERY SYSTEMS</b> .....	169
<i>Nayana S. Baste, Shweta H. Shahare and Atish S. Mundada</i>	
<b>INTRODUCTION</b> .....	169
Category I .....	170
Category II .....	170
Category III .....	170
Advantages of Mucoadhesive Drug Delivery System .....	170

Mucus Membrane .....	171
Mucus Structure, Composition, and Function .....	171
<i>Central Protein Core</i> .....	172
<i>Terminal Peptide Segments</i> .....	172
<b>MECHANISM OF MUCOADHESION</b> .....	173
Contact Stage .....	173
Consolidation Stage .....	173
Theories of Mucoadhesion .....	174
<i>The Electrostatic Theory</i> .....	174
<i>The Wettability Theory</i> .....	174
<i>The Diffusion Interpenetration Theory</i> .....	174
<i>The Adsorption Theory</i> .....	175
<i>The Fracture Theory</i> .....	175
<b>FACTORS AFFECTING MUCOADHESION</b> .....	175
Polymer-Related Factors .....	175
<i>Molecular Weight</i> .....	175
<i>The Concentration of Polymer</i> .....	175
<i>Flexibility of Polymer Chains</i> .....	176
<i>Spatial Confirmation</i> .....	176
<i>Swelling or Hydration</i> .....	176
<i>Hydrogen Bonding Capacity</i> .....	176
<i>Cross-linking Density</i> .....	176
<i>Charge</i> .....	176
Environment-Related Factors .....	177
<i>Polymer-substrate Interface pH</i> .....	177
<i>Initial Contact Time</i> .....	177
<i>Moistening</i> .....	177
Physiological Factors .....	177
<i>Mucin Turnover</i> .....	177
<i>Disease State</i> .....	177
<i>Concomitant Illnesses</i> .....	177
<i>Tissue Movement</i> .....	178
<b>SITES FOR MUCOADHESION</b> .....	178
Buccal Cavity .....	178
Vagina .....	178
Nasal Cavity .....	178
Eye .....	178
GI Tract .....	179
Esophagus .....	179
<b>MUCOADHESIVE DRUG DELIVERY SYSTEMS</b> .....	179
Tablets .....	179
Film .....	180
Patches .....	180
Gels and Ointments .....	180
<b>MUCOADHESIVE POLYMERS</b> .....	180
Ideal Characteristics of Mucoadhesive Polymers .....	181
First-Generation Mucoadhesive Polymers .....	181
Second Generation Mucoadhesive Materials .....	182
<i>Synthetic Polymers</i> .....	182
<i>Natural Polymers</i> .....	182
<i>Thiolated Polymers</i> .....	183

<i>Lectin-based Polymers</i> .....	183
<b>MUCOADHESIVE POLYMER EVALUATION TECHNIQUES</b> .....	183
In vitro Methods .....	183
<i>Shear Stress Method</i> .....	183
<i>Detachment Force Measurement</i> .....	184
<i>Unique Flow Chamber Technique</i> .....	184
<i>Wilhelmy Plate Technique</i> .....	185
<i>Tensiometer Method</i> .....	185
<i>Dual Tensiometer Method</i> .....	185
<i>Everted Sac Technique</i> .....	185
<i>Falling Liquid Film Technique</i> .....	186
<i>The Colloidal Gold Staining Method</i> .....	186
<i>Fluorescent Probe Method</i> .....	186
<i>Thumb Test Method</i> .....	187
<i>Modified USP Disintegration Apparatus</i> .....	187
<i>Flow Channel Method</i> .....	187
<i>Wash-off Test Method</i> .....	187
<i>Rheological Measurement Method</i> .....	188
<i>Modified Balance Apparatus</i> .....	188
In vivo Methods .....	188
<i>Gamma Scintigraphy Technique</i> .....	188
<i>GI transit using Radio-opaque Technique</i> .....	189
<i>Radioisotopes and Fluorescent Labeling Techniques</i> .....	189
<i>Surface Characterization Technique</i> .....	189
<b>ADVANCEMENTS IN MUCOADHESIVE DRUG DELIVERY SYSTEMS</b> .....	189
Nanotechnology Approach .....	189
<i>Enhanced Drug Bioavailability</i> .....	190
<i>Targeted Drug Delivery</i> .....	190
<i>Improved Stability and Protection</i> .....	190
<i>Versatile Formulation Options</i> .....	190
<i>Recent Innovations and Applications</i> .....	190
Microneedle-based Drug Delivery Systems .....	191
<i>Oral Mucosal Applications</i> .....	191
<i>Transdermal Applications</i> .....	191
<i>Innovations in Microneedle Design</i> .....	191
<b>CONCLUSION</b> .....	192
<b>REFERENCES</b> .....	192
<b>CHAPTER 6 GASTRORETENTIVE DRUG DELIVERY SYSTEMS</b> .....	197
<i>Deepak A. Kulkarni, Rushikesh S. Sherkar, Avinash K. Kudhekar, Chaitali S. Shirsathe and Swaroop R. Lahoti</i>	
<b>INTRODUCTION</b> .....	197
<b>PHYSIOLOGY</b> .....	198
<b>NEED OF GRDDS</b> .....	200
<i>Suitable Drug Candidates for GRDDS</i> .....	200
<i>Advantages and Disadvantages Associated with GRDDS</i> .....	201
<b>MECHANISM OF GASTRIC RETENTION</b> .....	202
<i>Bio-adhesive and Mucoadhesive Systems</i> .....	202
<i>Swelling and Expandable Systems</i> .....	203
<i>Magnetic Systems</i> .....	204
<i>High-density Systems</i> .....	204

Superporous Hydrogels .....	204
Ion-exchange Resin Systems .....	204
Floating Systems .....	205
<i>Effervescent systems</i> .....	205
<i>Non Effervescent Systems</i> .....	205
<b>GASTRORETENTIVE DRUG DELIVERY SYSTEMS</b> .....	206
Mucoadhesive System .....	206
Magnetic Tablet .....	209
Superporous Hydrogel .....	209
Floating System .....	210
Effervescent Floating Tablet .....	211
<i>Gas-generating Effervescent Floating System</i> .....	211
<i>The Volatile Oil Containing Effervescent Floating System</i> .....	212
Non-Effervescent Floating System .....	212
<i>Hydrodynamically Balance System (HBS)</i> .....	212
<i>Matrix Bilayer Tablet</i> .....	213
<i>Microballoons</i> .....	213
Floating Beads .....	214
High-Density System .....	214
Ion-exchange Resin System .....	214
Swellable System .....	215
Raft Forming System .....	215
Expandable System .....	216
3D Printing Technology in GRDDS .....	216
<b>ADVANCED NANOMATERIALS FOR GRDDS</b> .....	218
<b>POLYMERS USED IN GRDDS</b> .....	220
Polymers used in Floating Systems .....	220
Polymers used in Mucoadhesive/Bioadhesive systems .....	221
Polymers used in Swelling/Expanding Systems .....	221
Polymers Used in Superporous Hydrogels .....	222
<b>EVALUATION OF GRDDS</b> .....	223
In Vivo Assessment .....	223
Gastroscopy .....	223
Scintigraphy .....	223
Radiology/x ray Technique .....	224
Magnetic Resonance Imagining (MRI) .....	224
Ultrasonography .....	224
In Vitro Assessment .....	225
In Vitro Techniques for Expanding Dosage Forms .....	225
<b>LIMITATIONS OF GRDDS</b> .....	226
<b>PATENT SCENARIO OF GRDDS [151, 195]</b> .....	227
<b>CONCLUSION</b> .....	228
<b>REFERENCES</b> .....	228
<b>SUBJECT INDEX</b> .....	243



## FOREWORD I

I extend my heartfelt gratitude to all the authors who gave their valuable input in finalizing this book and to the editor for completing a monumental task. This book covers a detailed review of different drug delivery systems. The authors provide valuable insights into many delivery systems in a clear and concise manner. I found each and every article to be worth reading. The topics covered in this volume show elementary to current developments in drug delivery systems. This book contains more than enough references, to both primary and secondary sources, for those wanting to learn more about drug delivery systems. In my opinion, this book is a thought-provoking book that would be of interest to students, professors, and industry personnel. It can be used as supplementary material for teaching drug delivery systems at an undergraduate or postgraduate level and can be a great read for undergraduate and postgraduate students of pharmacy.

**P. R. Vavia**  
Department of Pharmaceutics  
Institute of Chemical Technology  
Mumbai, India

## FOREWORD II

The field of drug delivery systems has witnessed remarkable advancements over the past few decades, driven by the need for more effective, targeted, and patient-friendly therapeutic options. "Novel Drug Delivery Systems (NDDS)" is a comprehensive compilation of the latest innovations and research in this dynamic field, offering valuable insights into the development and application of advanced drug delivery technologies.

This book, meticulously curated by experts in the field, represents a comprehensive exploration of various controlled-release technologies that are reshaping the way medications are developed and delivered for patient compliance.

This book, meticulously curated by experts in the field, represents a comprehensive exploration of various controlled-release technologies that are reshaping the way medications are developed and delivered for patient compliance.

Microencapsulation is elucidated as a powerful tool augmenting controlled drug release mechanisms. Similarly, muco-adhesive, gastro-retentive, and naso-pulmonary drug delivery systems are meticulously explored, highlighting their specialized mechanisms and therapeutic advantages in treating diverse medical conditions.

The chapters dedicated to transdermal and ocular drug delivery systems underscore the innovative strides made in enhancing patient compliance and therapeutic outcomes through non-invasive delivery routes. Nanotechnology, a rapidly advancing frontier, is explored for its potential to revolutionize drug delivery precision and efficacy.

Furthermore, the development of implantable and controlled-release injectables is detailed, underscoring their role in sustained delivery and personalized medicine approaches. Each chapter is authored by leading experts, ensuring the content is not only authoritative but also at the forefront of current research and application.

"Novel Drug Delivery Systems (NDDS)" serves as an indispensable resource for researchers, academicians, and pharmaceutical professionals navigating the dynamic landscape of drug delivery. Each chapter is meticulously crafted to offer comprehensive coverage and depth, making this book an essential addition to the library of anyone involved in pharmaceutical sciences.

I commend the editors and contributors for their scholarly contributions and dedication, which have culminated in this authoritative reference. I trust this book will inspire further research and innovation in the field of drug delivery systems.

Warm regards,

**Sandip Tiwari**  
Head of Technical Services  
Pharma Solutions BASF Corporation, 500 White Plains Road  
Tarrytown, NY 10591

## PREFACE

We are delighted to present the first edition of our book, which focuses on Controlled Drug Delivery Systems (CDDS). In the rapidly advancing realm of pharmaceutical sciences, CDDS has emerged as a crucial innovation that enhances therapeutic efficacy and patient care. This book, crafted with the international readership in mind, seeks to provide a comprehensive understanding of the fundamental and practical aspects of controlled drug delivery systems.

This edition includes six carefully selected chapters, each authored by experts in the field. The book begins with Chapter 1, "Controlled Drug Delivery Systems: Concepts and Rationale," which lays the foundation for understanding the principles behind CDDS. It provides the necessary context and insight into why controlled release systems have become integral in modern therapy.

In Chapter 2, "Pharmacokinetic Considerations for Controlled Release Dosage Forms," the focus shifts to the essential pharmacokinetic aspects that influence the design and performance of controlled release systems. This chapter bridges the gap between theoretical knowledge and clinical application, ensuring readers grasp the critical factors affecting drug release and absorption.

Chapter 3, "Polymers: Backbone of Controlled Drug Delivery," delves into the world of polymers, emphasizing their indispensable role as the building blocks of many drug delivery systems. This chapter explores the design, development, and applications of various polymers in achieving desired drug release profiles.

Microencapsulation is the focus of Chapter 4, "Microencapsulation as a Tool for Controlled Drug Delivery." This chapter introduces readers to the concept and utility of microencapsulation technology in protecting drugs, controlling release rates, and improving stability, offering an in-depth look at a critical tool in the formulation of controlled release dosage forms.

Chapter 5, "Comprehensive Insights into Muco-Adhesive Drug Delivery Systems," addresses the specific niche of muco-adhesive systems, providing insight into their potential to enhance drug absorption and prolong residence time at the target site. The application of this technology offers promising solutions to various therapeutic challenges.

Finally, Chapter 6, "Gastroretentive Drug Delivery Systems," rounds off the book with a thorough exploration of gastroretentive technologies. This chapter presents innovative strategies to improve drug retention in the gastrointestinal tract, ensuring optimal drug delivery to the site of action.

Our goal with this book is to provide a robust resource for students, researchers, and professionals in the pharmaceutical sciences. By offering both theoretical foundations and practical insights, we hope to foster a deeper understanding of controlled drug delivery systems and inspire further innovation in this important field.

We extend our heartfelt thanks to the contributing authors, whose expertise and dedication have made this book possible. We are confident that the knowledge shared within these pages will serve as a valuable tool in the continued advancement of pharmaceutical sciences on a global scale.

**Atish S. Mundada**

Department of Pharmaceutics  
SNJBs SSDJ College of Pharmacy  
Chandwad, Nashik, Maharashtra, India

&

**Alap Chaudhari**  
Teva Pharmaceutical  
United States

## DEDICATION

*I would like to dedicate this book  
To  
My Late Grandfather,  
Whose love and Teachings have been guiding light throughout my life  
To  
My family Members*

**Atish S. Mundada**

*I would like to dedicate this book  
To  
My family and Friends*

**Alap Chaudhari**

## List of Contributors

- Atish S. Mundada** Department of Pharmaceutics, SNJBs SSDJ College of Pharmacy, Chandwad, Nashik, Maharashtra, India
- Avinash K. Kudhekar** Department of Pharmaceutics, Srinath College of Pharmacy, Aurangabad, Maharashtra, India
- Chaitali S. Shirsathe** Department of Pharmaceutics, Srinath College of Pharmacy, Aurangabad, Maharashtra, India
- Deepak A. Kulkarni** Department of Pharmaceutics, Srinath College of Pharmacy, Aurangabad, Maharashtra, India
- Deepak S. Khobragade** Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research, Sawangi (M), Wardha, India
- Hitesh V. Shahare** Department of Pharmaceutical Chemistry, SNJBs SSDJ College of Pharmacy, Chandwad, Nashik, Maharashtra, India
- Kavita Suthar** Department of Pharmaceutical Quality Assurance, SSR College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Sayli, Silvassa-396230, Union Territory of Dadra Nagar Haveli & Daman Diu, India
- Mrunali S. Potbhare** Swami Samarth College of Pharmacy, Dhamangaon, Wardha, Maharashtra, India
- Moreshwar P. Patil** Department of Pharmaceutics, METs Institute of Pharmacy, Bhujbal Knowledge City, Nashik, India
- Nayana S. Baste** Department of Pharmaceutics, SNJBs SSDJ College of Pharmacy, Chandwad, Nashik, Maharashtra, India
- Nayana S. Baste** Department of Pharmaceutics, SNJBs SSDJ College of Pharmacy, Chandwad, Nashik, Maharashtra, India
- Princy Shrivastav** Department of Pharmaceutical Chemistry, SSR College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Sayli, Silvassa-396230, Union Territory of Dadra Nagar Haveli & Daman Diu, India
- Rajendra T. Mogal** Department of Pharmaceutics, METs Institute of Pharmacy, Bhujbal Knowledge City, Nashik, India
- Rushikesh S. Sherkar** Department of Pharmaceutics, Srinath College of Pharmacy, Aurangabad, Maharashtra, India
- Shweta H. Shahare** Kalyani R.G. Sapkal Institute of Pharmacy, Anjaneri, Nashik, Maharashtra, India
- Surendra S. Agrawal** Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research, Sawangi (M), Wardha, India
- Swaroop R. Lahoti** Department of Pharmaceutics, Y. B. Chavan College of Pharmacy, Aurangabad, Maharashtra, India
- Vipul D. Prajapati** Department of Pharmaceutics, SSR College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Sayli, Silvassa-396230, Union Territory of Dadra Nagar Haveli & Daman Diu, India

## CHAPTER 1

# Controlled Drug Delivery Systems: Concepts and Rationale

Vipul D. Prajapati<sup>1\*</sup>, Princy Shrivastav<sup>2</sup> and Kavita Suthar<sup>3</sup>

<sup>1</sup> Department of Pharmaceutics, SSR College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Sayli, Silvassa-396230, Union Territory of Dadra Nagar Haveli & Daman Diu, India

<sup>2</sup> Department of Pharmaceutical Chemistry, SSR College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Sayli, Silvassa-396230, Union Territory of Dadra Nagar Haveli & Daman Diu, India

<sup>3</sup> Department of Pharmaceutical Quality Assurance, SSR College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Sayli, Silvassa-396230, Union Territory of Dadra Nagar Haveli & Daman Diu, India

**Abstract:** Modern pharmaceutical research and development has evolved to rely heavily on controlled drug delivery systems because they provide creative ways to improve therapeutic results while reducing side effects. The underlying ideas and justification for controlled drug delivery systems are covered in detail in this chapter. Beginning with a discussion of the drawbacks of conventional drug delivery techniques and the benefits of controlled release, the chapter explains the need for controlled drug delivery systems in modern medicine. The requirements for the design and formulation of controlled drug delivery systems have also been discussed in the chapter. The concepts of controlled drug release, which cover a variety of mechanisms, including diffusion, erosion, and osmosis, take up a sizeable section of the chapter. Additionally, emphasis is put on the function that mathematical modeling plays in predicting and optimizing drug release characteristics. It examines the wide spectrum of therapeutic uses for controlled drug administration, such as the treatment of chronic pain, cancer, diabetes, and other chronic disorders. The chapter also illuminates the future trends of such drug delivery systems like nanotechnology, personalized medicines, and advancements in medical devices. It also explores regulatory aspects and challenges involved in the design and commercialization of these systems, placing emphasis on the necessity of stringent quality control and safety evaluations. In conclusion, this chapter is a useful resource for researchers, scientists, and medical experts who want to understand underlying ideas and justifications of controlled drug delivery systems.

---

\* Corresponding author Vipul D. Prajapati: Department of Pharmaceutics, SSR College of Pharmacy (Permanently Affiliated to Savitribai Phule Pune University), Sayli-Silvassa Road, Sayli, Silvassa-396230, Union Territory of Dadra Nagar Haveli & Daman Diu, India; E-mail: vippra2000@yahoo.com

**Keywords:** Controlled drug delivery, Digital health, Drug release kinetics, Implantable devices, Nanoparticle-based delivery, Personalized medicine, Transdermal drug delivery.

## INTRODUCTION

### Historical Overview

For more than sixty years, controlled drug delivery systems (CDDSs) have been available on the market [1]. The term-controlled drug delivery describes the release of a medicine gradually and in a controlled manner. Spansule® was the first CDDS that had 12 hours of release time and was developed by Smith, Klein, and French laboratories. Spansule laboratory used this mechanism to control the dissolution of the drug core by forming a barrier around it, *i.e.*, a polymer coat, to prevent the degradation of the drug by gastrointestinal (GI) fluids. After this, various formulations were developed based on this mechanism. Other mechanisms are also coming into the picture after the rapid success of dissolution-controlled systems, namely diffusion-controlled, osmotic-controlled, and ion-exchange-controlled systems [2]. The evolution of CDDS is classified based on generations; the first generation of CDDSs was developed between 1950-1980, when most oral and transdermal dosage forms were formulated. First generation of drug delivery usually dealt with overcoming physicochemical barriers, and the most commonly used mechanisms were dissolution and diffusion-controlled systems for the delivery of drugs [3]. The 2<sup>nd</sup> generation of CDDSs was difficult as compared to the first generation and was focused more on physicochemical barriers. Most of the 2<sup>nd</sup> generation drug delivery was focused on the formulation of parenteral. The 1<sup>st</sup> generation was more successful as the manipulation of the drug's physicochemical properties was easy, whereas 2<sup>nd</sup> generation also focused on the body's response to the drug rather than the drug's profile. The 3<sup>rd</sup> generation was more advanced in terms of drug delivery. It focused mainly on formulation barriers and biological barriers. Formulation barriers include poor solubility of drugs and initial burst release (*i.e.*, the drug is initially released in a significant quantity before the release rate stabilizes.) [4]. Today, drug delivery systems continue to evolve, with emerging nano-scale delivery systems being developed for the management of different illnesses. Fig. (1) highlights the evolution of drug delivery systems.

### Rationale Behind CDDS

To solve problems with conventional drug delivery techniques, CDDSs were developed. Modifying the pharmacokinetics and pharmacodynamics of pharmacologically active drugs by changes in physiological factors, molecular



structures, or new drug delivery methods is the main objective of controlled drug delivery [5, 6]. The following are some of the reasons why CDDSs are important:




Fig. (1). Evolution of drug delivery systems.

- For traditional dosage forms, the only flexible factors for each medication are the dosage (D) and the frequency of administration (C). Each drug possesses a specific therapeutic range. When the concentration of a drug falls below the Minimum Effective Concentration (MEC), it fails to produce its desired therapeutic effect, and when it exceeds the Maximum Safe Concentration (MSC), it can lead to harmful side effects. The therapeutic index is a measure calculated as the ratio between  $LD_{50}$  (median lethal dose) and  $ED_{50}$  (median effective dose). Whereas in the case of controlled drug delivery, it offers the constant release of drugs between the range of MEC and MSC, as shown in Fig. (2).
- Patients typically find drugs with short half-lives administered through frequent daily injections or tablets less appealing than the same compounds released gradually through a once-daily oral dose, a semi-annual implant, or a three-day skin patch. The inconvenience of complex dosing schedules can lead to reduced effectiveness, as many patients tend to skip doses when required to adhere to such regimens. Hence, CDDS lowers the medication level, therefore increasing safety and minimizing adverse effects.
- To ensure that a drug is used to its maximum potential with minimal side effects and in the shortest possible time, drug developers can optimize its biopharmaceutics, pharmacokinetics, and pharmacodynamics properties. This can be achieved by employing several strategies, such as lead optimization, half-life optimization, potency and specificity optimization, molecular property design, and choosing the most suitable route of administration. By doing so,

**CHAPTER 2****Pharmacokinetic Considerations for Controlled-release Dosage Forms****Deepak S. Khobragade<sup>1,\*</sup>, Surendra S. Agrawal<sup>1</sup> and Mrunali S. Potbhare<sup>2</sup>**<sup>1</sup> *Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research, Sawangi (M), Wardha, India*<sup>2</sup> *Swami Samarth College of Pharmacy, Dhamangaon, Wardha, Maharashtra, India*

**Abstract:** The pharmaceutical industry has shown significant interest in controlled-release dosage forms due to their ability to improve pharmacological therapy by providing prolonged and regulated drug administration. The pharmacokinetic properties of a medicine are essential in establishing its efficacy and safety in a therapeutic setting. Controlled-release dosage forms offer significant advantages, such as reduced dosing frequency, improved patient compliance, and fewer adverse effects. To maximize the use of these benefits, it is critical to understand the complex interplay between formulation design, pharmacological properties, and controlled release systems pharmacokinetics. This chapter examines the pharmacokinetic aspects of controlled-release formulations, providing insight into their drug-release methods, absorption, distribution, metabolism, and excretion. The chapter also delves into the various elements that influence the rate of drug release from controlled-release dosage forms. These aspects include mechanisms such as diffusion, dissolution, and erosion. This study also investigates the impact of these mechanisms on medication absorption in the gastrointestinal tract and their influence on the drug's pharmacokinetic characteristics. Furthermore, the chapter emphasizes the importance of employing modeling and simulation approaches to predict the behavior of pharmaceuticals released from controlled-release formulations. Furthermore, the chapter undertakes an endeavor to examine the impact of pharmacokinetic parameters on the dosing schedule, therapeutic monitoring, and methods to enhance bioavailability. The chapter also discusses the importance of tailored drug delivery methods for specific patients, as well as the potential of personalized medicine. Understanding the pharmacokinetic parameters of controlled-release formulations is critical for optimizing pharmaceutical treatment. Gained knowledge can guide the development of innovative drug delivery methods, enhance patient outcomes, and accelerate pharmaceutical sector advancements.

**Keywords:** Absorption, Distribution, Drug action, Excretion, Metabolism, Pharmacokinetic, Plasma drug concentration, Pharmacokinetic, Steady state.

\* **Corresponding author Deepak S. Khobragade:** Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research, Sawangi (M), Wardha, India; Tel: 106472117/6301443987; E-mail: ksdeepak31@gmail.com

## INTRODUCTION

Pharmaceutical research has made great progress in the field of controlled drug delivery systems (CDDSs). CDDSs provide tailored solutions to improve drug therapy by ensuring the maintenance of therapeutic levels of medicine over an extended or desired period of time. These formulations minimize side effects, reduce the frequency of administration, improve patient adherence, and ultimately increase therapeutic outcomes. A thorough understanding of pharmacokinetic principles is a must to ensure and achieve efficacy, safety, and reliable drug delivery patterns from CDDS. Pharmacokinetics is the scientific study of medication absorption, distribution, metabolism, and excretion (ADME) in the body. The knowledge of pharmacokinetics is vital for the rational conception and evaluation of formulations for controlled release. The study of pharmacokinetics aids in our understanding of how drugs enter the body and interact with biological processes. It also provides crucial details on the release of medications from various dosage forms, including liposomes, transdermal patches, sustained-release tablets, and microspheres [1-3].

The pharmacokinetic parameters that are essential for the creation and enhancement of CDDS are attempted to be thoroughly examined in this investigation. The book explores the intricate relationship that exists between a medication's characteristics, physiological factors, and formulation-specific properties. The combined effect of these factors dictates how controlled-release formulations behave pharmacokinetically. This research offers a thorough analysis of the processes involved in medication absorption, distribution, metabolism, and excretion. It tries to make clear the primary variables that affect how quickly medications are released from the body and how well they are absorbed by the body [4, 5].

Gaining therapeutic goals and reducing the likelihood of giving too little or too much medicine depends on an understanding of the complex processes involved in the body's processing of controlled-release pharmaceuticals. Several parameters, including drug solubility, permeability, dissolution rate, particle size, and formulation excipients, have a substantial impact on medication absorption and distribution. Moreover, physiological factors that affect medication release and distribution throughout the body include enzyme activity, pH fluctuations, and gastrointestinal motility [6].

To ensure a consistent and dependable medicine distribution, it is also essential to carefully adjust the delicate balance between the efficacy of therapy and the kinetics of drug release. Sometimes, the release rate and duration of the formulation need to be carefully adjusted to match the drug's pharmacodynamic

properties and therapeutic window in order to get the optimal plasma concentration-time profile. Moreover, problems like dosage proportionality, dose dumping, and food-drug interactions necessitate a thorough pharmacokinetic review when developing a formulation [7].

In the end, successfully developing and implementing controlled-release drug forms require a thorough grasp of pharmacokinetic principles and how to apply them to formulation optimization. Researchers and pharmaceutical scientists may completely utilize controlled release technologies to increase patient adherence, boost drug therapy efficacy, and foster pharmaceutical innovation by including pharmacokinetic considerations in the formulation design process. In order to facilitate the development of controlled-release pharmaceutical forms, this chapter aims to offer comprehensive and in-depth guidance for comprehending the intricate topic of pharmacokinetics. The ultimate objective is to assist in converting scientific advancement into meaningful and efficient therapeutic interventions [8].

## **EXAMPLES OF CDDS**

### **Transdermal Patches**

Transdermal patches are commonly used for drugs requiring constant blood levels, such as pain relievers and hormone therapies. They provide controlled and continuous drug release through the skin [9].

### **Microspheres and Nanoparticles**

These small drug carriers release drugs gradually as they degrade or dissolve. They can be administered through various routes, including injection, inhalation, and oral ingestion [10].

### **Implants**

Implantable devices can release drugs over an extended period, often ranging from months to years. They are particularly useful for conditions requiring long-term therapy, such as contraception or hormone replacement [11].

### **Osmotic Pumps**

Osmotic pumps release drugs based on osmotic pressure gradients, enabling controlled and predictable drug delivery [12].

**CHAPTER 3****Polymers: Backbone of Controlled Drug Delivery****Shweta H. Shahare<sup>1,\*</sup>, Hitesh V. Shahare<sup>3</sup>, Nayana S. Baste<sup>2</sup> and Atish S. Mundada<sup>2</sup>**<sup>1</sup> Kalyani R.G. Sapkal Institute of Pharmacy, Anjaneri, Nashik, Maharashtra, India<sup>2</sup> Department of Pharmaceutics, SNJBs SSDJ College of Pharmacy, Chandwad, Nashik, Maharashtra, India<sup>3</sup> Department of Pharmaceutical Chemistry, SNJBs SSDJ College of Pharmacy, Chandwad, Nashik, Maharashtra, India

**Abstract:** The concept of a drug-delivery system (DDS) is not entirely new. Recent years have undoubtedly seen notable advancements in the identification and management of several illnesses. Medication administration to affected areas is an important part of DDS. A sufficient number of drug carriers are required to deliver an adequate amount of drug to the lesion. Polymers that expand and condense in reaction to pH levels outside of the body are being studied by researchers. The investigation is being carried out at a breakneck pace all over the world. Not only are advances in traditional technologies being made but innovations are also being developed and tested. The purpose of this chapter is to discuss a few of the polymer compounds that are utilized in controlled medication delivery systems. Both newcomers and scientists working in this fascinating field of applied polymer research will find the paper to be a valuable resource.

**Keywords:** Biodegradable polymers, Controlled drug delivery, Drug release method, Polymers.

**INTRODUCTION**

A polymer is a class of natural or synthetic substances composed of very large molecules called macromolecules, which are multiples of simpler chemical units called monomers. Polymers make up many materials in living organisms and are the basis of many minerals and man-made materials.

Poly indicates “many” in Greek, and meros indicates “units or parts”. Low-molecular-weight particles lack the distinct collaborative properties that make polymers so successful. The polymer formation is shown in Fig. (1).

---

\* **Corresponding author Shweta H. Shahare:** Kalyani R.G. Sapkal Institute of Pharmacy, Anjaneri, Nashik, Maharashtra, India; Tel: +8275584575; E-mail: hvshahare@gmail.com




Fig. (1). Polymer anatomy.

Polymers that are commonly found in nature include:

- Amino acids, disaccharides, and polysaccharides that include maltose, sucrose, and glycogen make up every type of protein.
- A nucleotide is a building block for nucleic acids that include DNA and RNA.

Polymers are utilized in medical devices due to their long-lasting and self-renewal potential. Polymers have long been employed as flow enhancers in liquids, suspensions, and emulsions. They also act as an excipients in capsule creation. Polymers are now entering the parenteral market as blood circulation enhancers, treatment stability boosters, and pharmaceutical property adjusters. To disguise a drug's bad flavor, they are additionally offered as a film coating product [1, 2].

They can now provide pharmaceuticals with complex features such as drug targeting. By simply lengthening their chains through cross-linking or by enhancing their hydrophobic or hydrophilic properties through copolymers and other groups, polymers can readily change their ability to dissolve in water, resulting in a varied spectrum of materials with multiple applications [3, 4].

## TYPES OF POLYMERS

The following list illustrates how several criteria are used to classify polymers into various categories.

## **Classifications Based on Source of Origin**

### ***Natural Polymers***

Natural polymers are derived from natural sources, such as plants or animals. Some examples include cellulose, jute, leather, silk, wool, and rubber from plants [5].

### ***Semi-synthetic Polymers***

Semi-synthetic fibers such as viscous rayon, cupra ammonium silk, and acetate rayon are produced through simple chemical treatments designed to enhance the chemical and mechanical properties of natural fibers such as reliability and tensile strength.

### ***Synthetic Fibres***

Synthetic fibers are created in a laboratory by polymerizing basic chemical elements. Polyethylene and polystyrene, nylon, PVC, bakelite, teflon, synthetic rubber, and synthetic materials are examples [6, 7].

## **Classifications Based on the Structure**

### ***Linear Polymers***

These polymers are composed of long, slender chains of monomers linked together. There are no side chains on these chains. They have molecules that are tightly packed and have high melting points, tensile strengths, and densities. Examples include polyester, nylon, polyethylene, and PVC.

### ***Branching Polymers***

They have long, straight chains with numerous side chains. Due to the disorganized organization of its particles, they have poor density, tensile strength, and melting temperature. Polypropylene (side chain —  $\text{CH}_3$ ), glycogen, and amylopectin are a few examples.

### ***Network or Cross-Linked Polymers***

A three-dimensional network is formed by joining these monomeric components together. Cross-links are the type of connections involved. Because of their network framework, they are rigid and fragile.

## Microencapsulation as a Tool for Controlled Drug Delivery

Rajendra T. Mogal<sup>1</sup> and Moreshwar P. Patil<sup>1,\*</sup>

<sup>1</sup> Department of Pharmaceutics, METs Institute of Pharmacy, Bhujbal Knowledge City, Nashik, India

**Abstract:** Controlled drug delivery systems, which release drug/s in a predetermined manner, offer numerous advantages over conventional drug delivery systems. These advantages include improved bioavailability, reduced dose frequency, minimized fluctuations in plasma drug concentration, and sustained drug release. The major drawback of the unit dosage form is dose dumping, which can be effectively overcome by multiple unit dosage forms like microcapsules. The microencapsulation technique involves enclosing drug/s by a thin coating shell, and the resultant product is referred to as microcapsules. This technique has potential applications, especially in delivering enclosed drug/s in a controlled manner, protecting them from harsh environments, masking unpleasant tastes, and many more. Several techniques, such as mechanical processes, chemical processes, and physicochemical processes, are used to encapsulate drug/s. Drug release from microcapsules is predominantly facilitated by diffusion, whereas swelling and dissolution, erosion and degradation, and osmosis are minor mechanisms. The polymers, which can be natural or synthetic, play a stellar role in the controlled release of drug/s from microcapsules. Prepared microcapsules are characterized and evaluated by various techniques for shape, size, surface characteristics, drug release and release kinetics, rheological behavior, *etc.* Despite the significant promise, various constraints and restrictions hinder the use of microencapsulation technology, creating a gap between real-life clinical practice and its therapeutic applications. The current chapter provides a comprehensive analysis of the most recent techniques, characterization and evaluation techniques, challenges, and commercially available microencapsulated pharmaceutical products.

**Keywords:** Air suspension, Coacervation phase separation, Interfacial polymerization, Ionotropic gelation, Microencapsulation, Microcapsules, Vibrational jet extrusion.

---

\* Corresponding author Moreshwar P. Patil: Department of Pharmaceutics, METs Institute of Pharmacy, Bhujbal Knowledge City, Nashik, India; E-mail: moreshwar\_p\_iop@bkc.met.edu



## INTRODUCTION

Microencapsulation is a process in which active agents or core materials present in solids, liquids, or even gases are enclosed by a thin coating or shell. The approach originated in the late 1930s as an environment-friendly alternative to carbon ribbons and carbon paper, which were developed by the business machine industry. The finding of carbon paper and ribbons that emitted dyes upon impact by a typewriter key or pen pressure in the 1950s inspired the creation of various microencapsulated materials, such as pharmaceuticals. The initial study that prompted the advancement of pharmaceutical microencapsulation technology was published in 1931. This study primarily focused on the formulation of gelatin spheres using a gelatin coacervation method [1]. At this time, classifying microcapsules based on their size is not available. They can be classified according to their size as nanocapsules (size less than 1 nm), macrocapsules (size more than 1000  $\mu\text{m}$ ), and microcapsules (size range between 3 to 800  $\mu\text{m}$ ) [2].

Despite their comprehensible differences, the terms microparticles, microcapsules, and microspheres are often used interchangeably, creating confusion among readers. Microparticles are particles of size between 1 and 1000  $\mu\text{m}$ , regardless of their internal or external structure. In the category of microparticles, microspheres are spherical microparticles, while microcapsules are microparticles with a core contained by a substance that is apparently distinct from the core. The core material might exist in solid, liquid, or gas states. A typical microsphere formulation is thought to be composed of a fairly uniform blend of drug and polymer, whereas microcapsules have at least one separate compartment of drug along with additional components [3].


### Reasons for Microencapsulation

- To sustain or prolong the release of the drug from dosage form.
- To mask the unpleasant taste and undesirable odor of drugs.
- To modify the physical states of liquid drugs into solid powder as solids can be handled conveniently.
- To protect medications from environmental factors, for instance, light, humidity, oxygen, and heat. Microencapsulation cannot create a complete barrier against environmental influences but can offer a high level of protection from them.
- To separate incompatible substances *e.g.*, eutectic mixture.
- To reduce the volatility of substances that are volatile at room temperature *e.g.*, aspirin.

- To reduce gastric irritation.
- To reduce the hygroscopic tendency of substances.
- It can be employed for selective absorption of drugs from the gastrointestinal tract (GIT) *e.g.*, enteric-coated dosage form.
- Intrauterine contraceptive devices made using the microencapsulation technique have been suggested [3, 4].

### FORMULATION CONSIDERATION

For effective implementation of the microencapsulation process, an in-depth knowledge of the core and coating materials, stability, drug release kinetics, and the microencapsulation technique to be employed is required. One should appreciate that the possibility of different microcapsule compositions, qualities, and applications depends on the manufacturing process used. The composition of microcapsules is shown in Fig. (1).



**Fig. (1).** Composition of microcapsules.

#### **Core Material**

The core material refers to a particular substance that can exist in solid, liquid, or gaseous form and is intended to be coated. The solid core of a drug may consist of a blend of drug/s, diluents, stabilizers, excipients, and release rate modifiers. On the contrary, the liquid core may comprise components that are dispersed or dissolved. The ability to modify the composition of the core materials provides system flexibility, and utilizing these properties frequently results in the successful design and fabrication of microcapsules with desired features.

**CHAPTER 5****Comprehensive Insights into Mucoadhesive Drug Delivery Systems****Nayana S. Baste<sup>1,\*</sup>, Shweta H. Shahare<sup>2</sup> and Atish S. Mundada<sup>1</sup>**<sup>1</sup> *Department of Pharmaceutics, SNJB's S.S.D.J. College of Pharmacy, Chandwad, Nashik, Maharashtra, India*<sup>2</sup> *Kalyani R.G. Sapkal Institute of Pharmacy, Anjaneri, Nashik, Maharashtra, India*

**Abstract:** Mucoadhesive drug delivery systems have gained significant attention in the field of pharmaceutical research due to their ability to enhance drug bioavailability, prolong residence time, and improve therapeutic outcomes. This chapter provides a comprehensive overview of mucoadhesive drug delivery systems, highlighting their importance in overcoming various challenges associated with conventional drug delivery. The chapter commences by elucidating the physiological and biochemical aspects of mucosal surfaces, emphasizing the significance of mucoadhesion in optimizing drug absorption and distribution. It explores the diverse applications of mucoadhesive systems across different mucosal sites, including the buccal, nasal, ocular, vaginal, and gastrointestinal mucosa. Additionally, the mechanisms underlying mucoadhesion, such as hydrogen bonding, electrostatic interactions, and covalent bonding, are thoroughly examined. The chapter delves into the various classes of mucoadhesive polymers, such as natural, synthetic, and semi-synthetic polymers, highlighting their distinct properties, applications, and evaluations. The chapter addresses key considerations such as biocompatibility, safety, and regulatory aspects associated with the development of mucoadhesive formulations. In conclusion, this chapter serves as a valuable resource for researchers, scientists, and practitioners in the field of drug delivery, offering a comprehensive understanding of mucoadhesive drug delivery systems and their potential to revolutionize the delivery of therapeutic agents across mucosal membranes.

**Keywords:** Mucoadhesive DDS, Mucus membranes, Mucoadhesion mechanism, Mucoadhesion theory, Mucoadhesive polymers, Patient compliance.

**INTRODUCTION**

Mucoadhesion, which is the capacity of a formulation to stick to mucous membranes, holds a distinguished place among the different strategies for changing various pharmaceutical delivery systems to increase bioavailability. The

\* **Corresponding author Nayana S. Baste:** Department of Pharmaceutics, SNJB's S.S.D.J. College of Pharmacy, Chandwad, Nashik, Maharashtra, India; Tel: +7666517449; E-mail: nayana14180@gmail.com

key advantages of mucoadhesive drug delivery formulations are their enhanced bioavailability and decreased total dose of active medication, whether it is administered locally or systemically. Understanding the mechanism of interaction between the mucosal layer and the mucoadhesive formulation is the main obstacle to the successful formulation of the mucoadhesive drug delivery system [1]. According to the American Society of Testing and Materials, in the adhesion of polymeric material to the mucosal surface, interfacial or intermolecular forces may be developed. Bioadhesion is a process that occurs when one of the biological materials forms strong interfacial forces with another polymeric material over a sustained period. It is the capacity of a substance, either biological or synthetic, to remain adhered to mucosal tissue for an extended period. In terms of novel drug delivery systems, bioadhesion is the adhesion of a drug carrier system to a particular surface of a tissue or epithelial tissue. Mucoadhesion is the term used to describe the process when an adhesive attaches to a mucous membrane [2].

Three distinct forms of bioadhesion exist within biological systems:

### **Category I**

This form of bioadhesion emerges when two biological systems adhere to each other. Illustratively, instances include blood platelet aggregation and the natural wound healing process.

### **Category II**

This type involves the adherence of a biological phase onto a man-made base material. For instance, the formation of biofilms on implants and inserts, as well as the growth of cells in such environments, represents examples of this phenomenon.

Example: Development of biofilm on implants and inserts as well as cell growth.

### **Category III**

It involves the attachment of a synthetic component to biological tissue, for example, the adhesion of sealants to tooth enamel and synthetic hydrophilic polymers to epithelial cells [3].

### **Advantages of Mucoadhesive Drug Delivery System**

Comparing mucoadhesive delivery systems to other oral controlled-release drug delivery systems reveals various benefits, such as:

1. The residential time of drugs in the gastrointestinal (GI) tract is prolonged.
2. Increased residence time of dosage form at the site of administration results in high drug flux at the absorbing tissue and increased bioavailability of the drug.
3. Drug localization and targeting at an area of interest [4].

### Mucus Membrane

The moist linings on the walls of various body cavities, such as the gastrointestinal and respiratory tracts, are referred to as mucous membranes. Comprising a layer of connective tissue termed the lamina propria, these membranes are succeeded by an epithelial layer. This surface is commonly maintained in a moist state through the presence of a mucus layer (Fig. 1). Instances of multilayered or stratified epithelia encompass the esophagus, vagina, and cornea. Conversely, single-layered epithelia can be observed in the stomach, small and large intestines, and bronchi. The latter are adjacent to tissues housing specialized glands, like salivary glands, responsible for producing mucus onto the epithelial surface. Goblet cells, a member of the first category, immediately secrete mucus onto the epithelium's surfaces. This mucus may be present as a solution or suspended condition within the luminal fluid, or it may be seen as a layer that resembles gel that is adhered to the mucosal surface [4].




Fig. (1). Mucus membrane.

### Mucus Structure, Composition, and Function

The complex, thick, adherent secretion known as mucus is produced by specialized cells called goblet cells. It has been discovered that mucus performs a variety of functions in these areas, including lubrication for the passage of objects, maintenance of the moist epithelium layer, protection against pathogens and

## Gastroretentive Drug Delivery Systems

Deepak A. Kulkarni<sup>1,†</sup>, Rushikesh S. Sherkar<sup>1,†</sup>, Avinash K. Kudhekar<sup>1,†</sup>,  
Chaitali S. Shirsathe<sup>1,†</sup> and Swaroop R. Lahoti<sup>2,\*</sup>

<sup>1</sup> Department of Pharmaceutics, Srinath College of Pharmacy, Aurangabad, Maharashtra, India

<sup>2</sup> Department of Pharmaceutics, Y. B. Chavan College of Pharmacy, Aurangabad, Maharashtra, India

**Abstract:** Administration through the oral route is the most accessible and preferred due to its many advantages. Most of the drugs administered orally show poor bioavailability due to less residing time at the gastric absorption site. To boost the bioavailability of such drugs, it is important to extend the residing time of the drug in the upper GIT, which can be achieved by using gastroretentive drug delivery systems (GRDDS). There are multiple conventional and advanced gastroretentive systems based on various mechanisms, namely high-density systems, floating systems, magnetic systems, mucoadhesive systems, expandable systems, raft-forming systems, and many more. Novel techniques like 3D printing technology are also an emerging approach in the fabrication of GRDDS. Various *in vitro* and *in vivo* techniques are used for the analysis of GRDDS, like buoyancy time, gastroscopy, scintigraphy, ultrasonography, *etc.* This chapter is the comprehensive literature exploring GRDDS, including various principles in the fabrication of GRDDS, techniques of preparation of GRDDS, polymers used in the fabrication of GRDDS, evaluation of GRDDS, application of 3D printing in GRDDS, and patent scenario.

**Keywords:** Gastroretentive drug delivery, Mucoadhesive, Floating, Swellable systems, Effervescent system, Non-effervescent system.

### INTRODUCTION

The oral route is the most preferred route of drug delivery due to a wide variety of advantages that include the ease of drug administration, high patient compliance [1], and easy formulation, storage, and transport of these dosage forms. It also offers a large surface area for the passive absorption of the medicament [2]. This route is the most dominant way to deliver active ingredients to treat local gastrointestinal (GI) diseases with systemic diseases. The mouth, esophagus,

\* Corresponding author Swaroop R. Lahoti: Department of Pharmaceutics, Y. B. Chavan College of Pharmacy, Aurangabad, Maharashtra, India; E-mail: pharmlahoti@gmail.com

† These authors contributed equally to this work

stomach, small intestine, and colon are the components of the GI tract that play a role in food digestion and medication absorption.

Despite the obvious advantages, oral drug delivery also faces some challenges, such as the harsh environment of the gastric system, enzymatic activity, and regional pH [3]. Conventional systems of drug delivery fail to overcome these issues, which leads to the ineffectiveness of the drug and an increase in the dose administration frequency. To overcome these obstacles that emerged due to the harsh environment in the GI tract and other physiological barriers, significant attempts have recently been made, which are dependent on a better awareness of the healthy and pathological characteristics of the GI tract. The therapeutic range is the total serum abundance of a drug needed to achieve the therapeutic effect of a particular drug. To get the continuous impact of a drug, it is necessary to sustain the drug concentration in the therapeutic range with the help of frequent administration, which is responsible for fluctuation in drug plasma concentration [4]. This has led to the formulation of a controlled drug delivery system.

Controlled drug delivery systems (CDDS) are primarily considered for the prolonged release of drugs and to achieve stable plasma concentration for a longer period. The primary goals of controlled drug delivery are to increase drug efficacy by modifying the pharmacokinetics and pharmacodynamics of the pharmaceuticals, maintain drug concentration in the desired tissue, and decrease the number of administrations. However, it is less helpful for drugs with an absorption window in the upper GI tract due to the gastric transit time. Although the duodenum and jejunum show rapid absorption, the movement through this part is swift, which limits the scale of absorption [5]. To enhance the bioavailability of such drugs, it is vital to extend the residence time of the drug in the upper GI tract, which can be obtained by the use of a gastroretentive drug delivery system (GRDDS), which can endure the rough environment, grinding, crushing, and peristaltic movements, and which can also release the drug at a controlled rate in the GI tract. The created system should not impair gastric movability or ruin the mucosa lining of the stomach. GRDDS is important to achieve better drug efficacy and targeted drug delivery.

## **PHYSIOLOGY**

The digestive system travels from the mouth to the anus *via* the midsection of the body. The pharynx, esophagus, stomach, and small (which includes the duodenum, jejunum, and ileum) and large (which includes the cecum, appendix, colon, and rectum) intestines are the main components of the GI tract. The GI tract is a 9 meters long tube that appears from the esophagus to the anus, with some adjacent variations.

The oral cavity is protected by the oral mucosa and possesses favorable permeability, a moderate microenvironment, easy access to circulation, and good drug absorption. However, the greatest obstacles to drug delivery in the mouth are the smaller surface area of the oral cavity, saliva, and enzyme makeup of saliva [6].

The esophagus has a short residence time and low permeability, and it is not a target for drug delivery. The stomach is a muscular hollow organ located in the left upper portion of the abdominal cavity, beneath the diaphragm and liver. The three major functions of the stomach are digestion, churning, and limited absorption. Structurally, the stomach is divided into 4 sections: the cardia, fundus, corpus (body), and pylorus (Fig. 1). Its prime responsibility is to briefly store and crush food before releasing it gradually into the duodenum. Fundus and corpus are the reservoirs of undigested food, and at the same time, the antrum serves as a pump to help with gastric emptying *via* a pushing mechanism [7]. The pyloric area is an essential area for the mixing of food, and it also connects the stomach with the duodenum. It has a very acidic pH of about 1-2.5, and it helps to crumble food, deteriorate microbes [8], and degrade acid-unstable drugs [9].




Fig. (1). Anatomy of Stomach [10].



## SUBJECT INDEX

### A

Absorption 73, 75, 147  
 gastrointestinal 73  
 oral 75, 147  
 Acid 9, 17, 28, 58, 66, 88, 96, 97, 99, 100,  
 103, 104, 106, 112, 117, 118, 119, 132,  
 146, 147, 157, 160, 161, 182, 183, 211,  
 217, 218, 222  
 acrylic 106, 119, 182, 183, 222  
 alginic 99, 117  
 amino 88, 96, 117  
 boronic 117  
 citric 211  
 ferulic 147  
 glucuronic 58  
 glutamic 9  
 hyaluronic 17, 100  
 Hydrochloric 157  
 lactic 103  
 methacrylic 117, 160, 183  
 mineral 147  
 palmitic 161  
 phenylboronic 118  
 polyacrylic 132, 182  
 polyglutamine 104  
 polylactic 28, 103, 112, 217, 218  
 Sebacid 161  
 stearic 132, 217  
 tartaric 211  
 thioglycolic 183  
 Acidosis 30  
 Activity, mitochondrial 25  
 Adsorption theory 175, 202, 203  
 Aerosol drug delivery techniques 183  
 Agents 24, 110, 153, 205, 219  
 chemotherapeutic 24, 153, 219  
 flavor masking 110  
 gas-generating 205  
 Albumin, bovine serum 11, 147

### B

Behavior 39, 113, 117, 128, 223, 225  
 gastric 225  
 rheological 128  
 Bioadhesive system 202  
 Biotechnology industries 150  
 Biotransformation process 57  
 Blood platelet aggregation 170  
 Bovine serum encephalopathy (BSE) 97  
 Brain tumors 107

### C

Camera, capsule endoscopy 223  
 Cancer 1, 7, 11, 22, 23, 25, 29, 96, 107, 172,  
 219  
 breast 23, 25  
 ovarian 23  
 theranostics 25  
 Capsules, soft gelatin 97, 161  
 Carbohydrate-based polymers 98  
 Cellulose 89, 98, 101, 102, 115, 149  
 microcrystalline 101, 115  
 Chemotherapy, traditional 25  
 Coating techniques 18  
 Concentration 8, 49, 51, 55, 65, 67, 68, 71, 72,  
 137, 138, 143, 145, 147, 216  
 glyceride lipid 216  
 ionic 8  
 Concomitant illnesses 177  
 Condensation polymers 90  
 Copolymers 17, 88, 91, 103, 104, 107, 113,  
 119  
 acid-based 17  
 Corticosteroids 27  
 Cytotoxicity 183

### D

Degradation 2, 10, 18, 21, 29, 93, 95, 107,  
 145, 152, 157, 181, 190, 208

- enzymatic 107, 190
  - gastrointestinal enzyme 208
  - Delivery systems 4, 5, 8, 13, 14, 53, 128, 146, 151, 162, 170, 178, 221
  - anticancer drug 151
  - biodegradable drug 14
  - conventional drug 4, 53, 128, 146, 162
  - gastric retentive drug 178
  - oral controlled drug 221
  - oral controlled-release drug 170
  - oral drug 5
  - osmotic drug 8, 13
  - Detachment stress 188
  - Devices 12, 22, 23, 29, 44, 107, 108, 119, 201, 202, 212, 217
  - designing innovative drug-delivery 217
  - gastroretentive 201
  - Diseases 6, 25, 42, 101, 159, 172, 190, 191, 197, 210
  - infectious 172
  - inflammatory bowel 101
  - mucosal 191
  - pulmonary 6
  - Drug(s) 44, 45, 51, 52, 59, 63, 65, 66, 67, 74, 75, 80, 160, 182, 191
  - absorption 44, 45, 51, 52, 63, 65, 66, 67, 74, 75, 191
  - biotransformation 59, 80
  - lipophilic 52, 182
  - microencapsulated 160
  - Drug delivery 2, 3, 4, 23, 24, 25, 26, 27, 28, 30, 58, 80, 81, 146, 148, 150, 159, 160, 191, 197, 198, 199, 200, 220, 227
  - anticancer 25
  - gastrointestinal 227
  - liposomal 23
  - oral 198, 200
  - oral mucosal 191
  - transdermal 2, 28, 146
  - devices 27
  - methods 3, 58, 200
  - microencapsulation technology 160
  - plasma concentration 198
  - Drug metabolism 46, 53, 57, 58, 59, 62, 69
  - enzymes 59
  - Drug release 8, 20, 21, 87, 93, 94, 142, 143, 155, 157, 158, 162, 217
  - mechanism 8, 20, 93, 94, 142, 143, 155, 157, 158
  - method 21, 87
  - profiles 162, 217
- E**
- Electromagnetic vibrational mechanism 12
  - Electron microscopy 189
  - Electrostatic 174
  - hypothesis 174
  - theory 174
  - Endocytosis 182
  - Energy, thermal 92
  - Environment 11, 66, 98, 103, 115, 116, 146, 170, 172, 198, 208, 225
  - acidic 66
  - biological 146
  - gastric 208, 225
  - Enzyme activity 40, 53, 57, 68, 69, 76
  - hepatic 68
  - Enzyme glucose oxidase 117
  - Erosion 1, 10, 20, 21, 39, 64, 142, 143, 145, 206, 215, 220
  - based matrix system 10
  - controlled release systems 21
  - polymeric matrix's 21
  - European medicines agency (EMA) 19, 151
- F**
- Falling liquid film technique 186
  - Fibers 100, 223
  - nerve 100
  - optical 223
  - Fluorescent probe method 186
  - Forces, electrostatic 208
  - Fourier transform infra-red (FTIR) 155, 213
  - Functions 47, 68
  - cardiovascular 68
  - hepatic 47
- G**
- Gas(s) 129, 139, 172, 211, 212, 220, 224
  - compressed 139
  - generating effervescent floating system 211
  - inert 220
  - Gastric 130, 201, 202, 209, 217, 218, 219, 221, 223, 224, 227, 228
  - carcinoma 219
  - conditions 219

**Subject Index**

irritation 130  
residence system 227  
retention 201, 202, 209, 217, 221, 223, 224, 228  
retention system 218  
Gastroesophageal reflux disorder 213  
Gastrointestinal 2, 45, 67, 71, 73, 169, 171, 173, 179  
mucosa 169  
system 71, 173, 179  
tract disorders 67  
Genetic variants 69, 70  
GI 48, 213, 214, 215  
mucosa 213  
system 48, 214, 215  
Glucuronidation 60  
Gut microbiota 200

**H**

Hepatic 46, 52, 61, 71, 74, 208  
clearance 61, 71  
metabolism 52, 71, 74, 208  
microsomes 46  
High-performance liquid chromatography (HPLC) 157  
Hydrodynamically balanced system (HBS) 205, 206, 212  
Hydrogel-based drug delivery systems 23  
Hydrolysis 21, 46, 58, 112, 115  
Hydrophilic 7, 88, 107, 144, 147, 152, 172, 181, 203, 205, 211, 214, 216, 220, 222  
nature 172, 220  
polymers 7, 144, 147, 152, 181, 203, 205, 211, 214, 216, 222  
properties 88, 107  
Hyperthermia 177

**I**

Infections 29, 42, 178, 190, 191, 200, 201  
bowel 200  
fungal 178  
urinary system 201  
Inflammation 11, 27, 29, 96, 150, 178  
intestinal 150  
lung 27  
tissue 96  
Inflammatory bowel syndrome 101  
Influence 62, 68, 92

**Novel Drug Delivery Systems (Part 1) 245**

drug metabolism 68  
intermolecular forces 92  
of enzymes 62  
Insulin-loaded microcapsules 148

**K**

Kaposi's sarcoma treatment 23

**L**

Lipophilicity 55  
Liposomes 23, 25, 30, 40, 99, 108, 109, 190  
mitochondria-targeted 25  
Low crystalline powdered cellulose (LCPC) 102

**M**

Macromolecular drug delivery techniques 13  
Magnetic 11, 27, 28, 64, 116, 118, 119, 209, 223, 224  
elastomers 118  
energy 11  
field responsive polymers 118  
resonance imaging (MRI) 64, 209, 223, 224  
Medical devices 1, 19, 31, 88, 107  
biodegradable 107  
Medication(s) 23, 24, 39, 40, 42, 52, 53, 64, 65, 66, 67, 69, 74, 198  
absorption 39, 40, 52, 53, 64, 65, 66, 67, 74, 198  
antidiabetic 23  
diabetes 23  
metabolism 69  
therapy 24  
transporting 42  
Medicines 12, 29, 30, 31, 39, 40, 42, 46, 51, 54, 55, 59, 60, 62, 66, 67, 69, 74  
anticancer 42  
hydrophobic 12  
metabolized 59  
Mesoporous silica NPs (MSNs) 108  
Metabolic 60, 63, 69, 70, 71, 74  
pathways 60, 70, 71  
processes 69  
profiles 63, 74  
Metabolism, enzymatic 62, 74  
Metformin hydrochloride 150  
Microbial sources 95

Microcapsule(s) 128, 129, 130, 132, 142, 143, 144, 145, 146, 147, 148, 150, 154, 155, 156, 159, 160  
  drug-loaded 155, 159, 160  
  fabricated 154  
  swelling tests 156  
Microemulsion 161  
Microencapsulation 128, 130, 133, 137, 140, 146, 159, 162  
  mechanical 137  
  process 130, 140, 146  
  systems 162  
  technique 128, 130, 133  
  technology 128, 159  
Microfluidic systems 18  
Microneedle(s) 28, 191, 192  
  -based drug delivery systems 191, 192  
  for drug delivery 28  
Mucoadhesive 173, 176, 177, 182, 183, 188, 189  
  polymer evaluation techniques 183  
  properties 173, 176, 177, 182, 188, 189, 206, 221, 226  
Mucosa 180, 184, 185, 187, 191, 199, 206, 221, 226  
  gastric 206, 221, 226  
  intestinal 184, 185, 187  
  oral 180, 191, 199  
Mucosal 169, 179, 180, 187  
  irritation 179  
  membranes 169, 180, 187  
Mucus 171, 172, 173, 174, 175, 176, 177, 179, 181, 185, 188, 202, 203, 206  
  intestinal 179  
  natural 185

## N

Nanoparticle(s) 2, 23, 24, 108, 109  
  -based delivery 2  
  lipid-based 108  
  lyotropic liquid crystalline 109  
  -mediated drug delivery systems 23  
  polymer-based 24  
Natural 132, 146, 170, 219  
  flavonoid 219  
  polycation 146  
  polysaccharides 132  
  wound healing process 170  
Nature, non-flammable 139

Nerve abnormalities 107  
Non-compartmental analysis 75  
Non-covalent interactions 9  
Non-effervescent 197, 205, 212, 220  
  floating 212  
  floating system 212  
  systems 197, 205, 220

## O

Oil 138, 148, 150, 161  
  castor 161  
  essential 148  
  fennel 148  
  mineral 138  
One-step emulsification method 149  
Optical microscopy 154  
Oral delivery systems 147  
Oscillations 49, 62  
Osmosis 1, 20, 21, 64, 119, 128, 142, 145, 157  
  -based release 21  
Osmotic 13, 21, 143, 145  
  pressure 13, 21, 143, 145  
  systems 13, 21

## P

Polymer(s) 115, 118, 119, 176, 177, 174, 182, 189, 202, 209, 215, 219, 220, 221  
  anionic 182  
  bioadhesive 174, 202, 220, 221  
  biodegradation 115  
  cationic 177, 182  
  cationic-charged 176  
  degradation 189  
  enzyme-responsive 118  
  erosion 215  
  irradiation-sensitive 119  
  network 209, 219  
Polymerization process 90, 91  
Positron emission tomography (PET) 64  
Printing 28, 197  
  technique 28  
  technology 197  
Process 128, 133, 139  
  freeze-drying 139  
  mechanical 128, 133  
Production, metabolite 58  
Properties 15, 16, 40, 41, 92, 101, 102, 105, 107, 112, 118, 172, 202, 220, 222

## **Subject Index**

antibacterial 105  
cytoadhesive 202  
gastroretentive 222  
mucus bacteriostatic 172  
Protein(s) 46, 55, 67, 88, 95, 101, 103, 104,  
132, 138, 139, 172, 183, 190, 191  
-based polymers 95  
binding 46  
globular 172  
plasma 55, 67  
Proteolysis 97  
Proton pump inhibitors (PPIs) 66  
Psychiatric system 22

**R**

Raman spectroscopy 155  
Ramifications 201  
Renal function 70

**S**

Salivary secretions 178  
Scanning tunneling microscopy (STM) 189  
Skin 25, 29  
cancer 25  
disorders 29  
Spatial resolution 223, 224  
Spray drying technique 147  
Sterilization process 114  
Stomach environment 203  
Synthetic fibers 89

**T**

Techniques 28, 77, 78, 114, 128, 133, 138,  
139, 141, 142, 153, 154, 162, 183, 188,  
223  
analytical 154  
contemporary 114  
robust 138  
Technologies 19, 31, 87, 111, 139, 159, 192,  
216, 217, 218  
microfluidic 19  
traditional 87  
Tensile strength 89, 90, 93, 225, 226  
Therapeutic 6, 11, 22, 24, 27, 30, 40, 41, 46,  
49, 55, 56, 57, 62, 63, 108, 111, 128,  
169, 179, 192, 198, 201, 208, 212, 227,  
228

## **Novel Drug Delivery Systems (Part 1) 247**

agents 11, 169, 201, 212, 227  
applications 22, 30, 128  
benefits 46, 49, 62  
effects 46, 57, 63, 198, 208  
material 27  
outcomes 40, 49, 55, 56, 111, 169, 192, 228  
substances 6, 24, 108, 179  
window 41  
Therapy 6, 25, 27, 40, 42, 44, 80, 160, 219  
clinical 160  
hormonal 6  
photothermal 25  
Thermal 92, 155  
properties 92  
research techniques 92  
Thermogravimetric analysis (TGA) 155  
Thermoplastic polymers 91  
Thermoresponsive polymers 116  
Throat, sore 201  
Thumb test method 187  
Tissue(s) 11, 28, 29, 46, 55, 56, 57, 67, 68, 72,  
96, 104, 111, 170, 171, 184, 185, 188,  
190, 191  
absorbing 171  
biological 170  
cancerous 11  
connective 96, 171  
damage 29  
dermal 111  
penetration 55, 67  
vaginal 188  
Tooth enamel 170  
Toxic 29, 30, 56, 219  
effects 29, 30, 56, 219  
substances 29  
Transdermal 6, 23, 42, 43, 182, 191  
adhesives 182  
drug delivery systems (TDDSs) 6, 42  
patches stick 43  
systems 23  
Transfer 28, 174, 207  
electron 174, 207  
Transfersomes 108  
Transformative shift 30  
Transport 104, 200  
pathways 200  
peptide 104  
Transporters 23, 52, 65, 68, 72  
hydrogel drug 23

Treatment 22, 23, 24, 25, 26, 27, 43, 53, 54,  
57, 58, 67, 68, 80, 218, 219  
hormonal 43  
painful 22  
ulcer 219  
Triblock copolymer 108  
Trigger-based design 8  
Tumor 4, 11, 23, 25, 96  
malignant 23

## U

Ultrasonic atomization 148  
Ultrasonography 197, 223, 224  
Ultrasound irradiation 116, 119  
UV radiation 20

## V

Vancomycin 150, 152  
-loaded trehalose 150  
Versatile formulation options 190  
Vibrating jet technique 138  
Vision difficulties 107  
Volatile 205, 212, 220  
liquids 205, 220  
oil 212

## W

Waals forces 90, 175, 182, 202, 203, 208, 221

## X


X-ray Diffraction (XRD) 155  
XRD technique 155



**Atish S. Mundada**

---

Prof. Atish S. Mundada is a passionate academician and a research driven individual. He is working as professor in pharmaceuticals and in-charge, Drug Regulatory Affairs department at SNJBs SSDJ College of Pharmacy, Chandwad, Nashik, Maharashtra, India. He completed graduation in 2000 from Government College of Pharmacy, Amravati and post graduation in pharmaceuticals from Department of Pharmaceutical Sciences, Nagpur University in 2003. He earned Ph.D. from Nagpur University in 2010. He has more than 50 national and international publications in the journals of repute with total citations of more than 1111. He has two Indian patents to his credit and a number of students have been awarded with Ph.D. under his guidance. He is serving as associate editor of American Journal of Biomedical Science and Research and has served as reviewer for various international journals. He received research grants from different funding agencies in India. He has published two international books and two national books and has 1 book chapter to his credit.



**Alap Choudhari**

---

Prof. Alap Choudhari is the director of TEVA Pharmaceutical since October 2017. He earned his Ph.D. from Nagpur University in 2007. He has three US patents to his credit and has many research publications in journals of repute. He has written 1 book and 1 book chapter. He has been serving in the pharmaceutical industry since 2007 and has worked with different pharmaceutical industries, such as Sun Pharmaceutical, Amneal Pharmaceuticals, NY, USA, Watson Pharmaceuticals, Florida, and Actavis Inc./Allergan, USA.